151 results about "Alphapapillomavirus" patented technology

This invention relates to a transdermal delivery system for treating skin related genetic diseases. More specifically, the present invention provides particles and methods for using pseudo-viruses, including those derived from the herpes and papillomaviruses, to deliver drugs to keratinocytes and basal membrane cells for the treatment of skin genetic disorders including Pachyonychia Congenita and Xeroderma Pigmentosum.

An in vitro method is provided for screening human female subjects to assess their risk of developing cervical carcinoma which comprises screening the subject for expression of mRNA transcripts from the E6 and optionally the L1 gene of human papillomavirus, wherein subjects positive for expression of L1 and/or E6 mRNA are scored as being at risk of developing cervical carcinoma. Kits for carrying out such methods are also provided.

The invention provides an sgRNA combined with immunogene to inhibit high risk HPV expression, a gene knockout vector thereof, and an application of the sgRNA and the vector. The sgRNA sequences of a human papilloma virus 16 type gene suitable for CRISPR-Cas9 targeting editing and a human PD-1 gene are selected, and the plasmid vector of the sgRNA and a CRISPR-Cas9 nuclease gene expression vector are transferred to HPV16+ human cervical carcinoma cells and HPV16+ transplantation tumor-bearing mice, and can obviously inhibit HPV16 expression and inhibit tumor growth. The gene expression vector prepared in the invention has the advantages of simple method steps, good sgRNA targeting property, high CRISPR-Cas9 knockout efficiency, accurate targeting splicing of high risk HPV16 type and PD-1 genes, efficient reduction of the expression of the high risk HPV16 type gene, and obvious inhibition of the tumor growth through combined application.

The present invention provides systems for identifying anti-viral agents. In particular, the invention encompasses reagents and strategies for identifying agents that inhibit or disrupt key protein-protein interactions that are important in the life cycle of papillomaviruses. The invention allows identification, production, and/or use of agents that reduce or inhibit the replication of HPV by inhibiting (e.g., precluding, reversing, or disrupting) the formation of the E1-E2 protein-protein complex. The invention also provides specific inhibitory agents, pharmaceutical compositions, and methods of using these inhibitors and pharmaceutical compositions for inhibiting viral replication in vitro. Methods are also described for the treatment and prevention of HPV infections and HPV-related diseases in patients.

Synthetic DNA molecules encoding papillomavirus proteins are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through stimulation of neutralizing antibody and cell-mediated immunity.

An assay for detecting HPV comprising treating the viral nucleic acid with an agent that modifies cytosine to form derivative viral nucleic acid, amplifying at least a part of the derivative viral nucleic acid to form an HPV-specific nucleic acid molecule, and looking for the presence of an HPV-specific nucleic acid molecule, wherein detection of the HPV-specific nucleic acid molecule is indicative HPV.

The present invention provides a purification method of human papillomavirus late protein L1 from escherichia coli. Virus-like Particles; the virus-like Particles with elctrophoresis purity more than 98 percent can be produced in a large scale through salt free precipitation, re-dissolving, ion exchange chromatography, hydrophobic interaction chromatography and renaturation of the L1 protein in the lysate supernatant of escherichia coli. With good immunogenicity, the virus particles can induce neutralizing antibodies towards homologous HPV virus, and can be used as a vaccine for preventing the infection of HPV.

The invention relates to truncated L1 proteins of a human papilloma virus (HPV), virus-like particles as well as a preparation method and application of virus-like particles. The invention particularly relates to HPV6-type, HPV11-type, HPV16-type, HPV18-type or HPV58-type truncated L1 proteins of the HPV, the virus-like particles as well as the preparation method and application of the virus-like particles.

Fusion polypeptides and aggregates of polypeptides comprising papillomavirus-derived antigens, and compositions thereof and their use e.g. with adjuvants for immunogenic and vaccine purposes in eliciting e.g. HPV-specific immune responses. The polypeptides can be purified to result in aggregates which when in solution or dispersion can pass through a sterilisation filter, and in amorphous aggregates. An example of such a polypeptide is a fusion protein of human papillomavirus proteins L2 and E7.

A method for detecting human papillomaviruses (HPV) in biological material is described, in which method nucleic acids are extracted/isolated from biological material and HPV-specific DNA is detected in the isolated nucleic acids. This method uses at least one of the nucleotide sequences SEQ ID No. 1 or SEQ ID No. 2 from the enclosed sequence listing or sequences which bind to sequences to which one of the sequences SEQ ID No. 1 or SEQ ID No. 2 binds or sequences which are complementary to the abovementioned sequences.

The invention relates to a polypeptide, in particular to a human papilloma virus coat protein L1 short peptide and relative application. The invention is characterized in that the sequence of the human papilloma virus coat protein L1 short peptide is N-EVNLKEKFSADLDQFPLGRKFLLQAGLKAK-C. The invention can simultaneously induce human papilloma virus coat protein L1 short peptide with immunity reaction on high risk type and low risk type, which can induce and form the antibody for various human papilloma virus (HPV) and coat protein (HPV L1), to check various HPV or HPV L1, while the antibody can be used in biological pharmaceutical engineering, to purify and prepare various HPV or HPV L1.

This invention relates to the detection of extracellular papillomavirus DNA in blood plasma or serum from a human or animal. In particular, the invention relates to the detection, identification, evaluation, or monitoring of neoplastic, premalignant or malignant disease associated with a papillomavirus. The invention thereby provides methods for the identification of individuals at risk for, or having, cervical dysplasia, cervical intraepithelial neoplasia, or cervical cancer.

The present invention discloses a primer, a probe, a DNA chip, and a test kit for diagnosis and genotyping of Human Papilloma Virus (HPV) as well as a method for testing HPV genotype. According to the present invention, it is possible to screen HPV genotypes with high sensitivity and specificity, and to diagnose infection by multiple HPV types which was not possible in other conventional HPV testing methods

The invention discloses a method for preparing a recombinant human papillomavirus 18-typed L1 protein with a pichia pastoris expression system and comprises the steps of loading an HPV 18 L1 gene in accordance with optimal design into an expression carrier, transforming pichia pastoris and cultivating a transformant, thus obtaining the recombinant human papillomavirus 18-typed L1 protein, which is self-assembled into virus-like particles inside a pichia pastoris body; wherein, nucleotide sequences of the HPV 18 L1 gene in accordance with optimal design are shown in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5 or SEQ ID NO.6. The HPV 18 L1protein that is prepared by the method of the invention has high expressed quantity. The invention further discloses a method for preparing a papillomavirus 18-typed infection vaccine with better activity by utilizing the virus-like particles of the recombinant HPV 18 L1 protein.

Compositions that include at least one protein that activates a Toll-like Receptor and includes at least a portion of at least one Toll-like Receptor agonist and at least a portion of at least one papillomavirus suppressor binding protein, papillomavirus transforming protein and papillomavirus capsid protein can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can further include an adjuvant and a carrier protein.

The invention relates to a human papilloma virus capsid protein L1 (HPVL1) peptide and preparation and application thereof. The HPVL1 peptide is a peptide segment of which the amino acid of the sequence is N end-Cys Thr Leu Thr Ala Asp Val Met listed Thr Tyr Ile His-C end, or is a peptide segment comprising the amino acid of the sequence and with a length less than 50 amino acids. In the invention, the peptide which is a very conservative peptide segment located on the surface of protein is sieved out by performing epitope forecasting and multi-sequencing comparison on the L1 proteins of 18 low-risk types and high-risk type HPV subtypes (6, 11, 16, 18, 52, 58 and the like); the antibody generated from induction can react with multiple types of HPVL1, and can be used for the detection of the multiple types of HPVL1, in particular to the application of precancerous lesions detection of human cervical carcinoma; and the antibody aiming at the peptide segment also can be used for purifying and preparing the multiple types of HPVL1. In addition, the invention also provides the applications of the peptide segment used as multiple types of HPV antiserum and detected matters of monoclonal antibody.

The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.

The present invention relates to an accurate, sensitive, and efficient sequential or concurrently sequential method for molecular diagnosis of human papillomavirus (HPV)-based disease, where the method improves the accuracy and reliability of diagnostic and prognostic assessments of HPV-based disease. The method of the invention comprises a primary screen of a sample for HPV nucleic acids, followed by a secondary screen for molecular markers, such as proliferation and cell cycle control group protein markers. The sequential or concurrently sequential method significantly reduces the number of false positive results.

The invention relates to a high-efficiency and simple method for detecting a human papilloma virus (HPV) neutralizing antibody, which can be applicable to high-throughput detection of the human papilloma virus neutralizing antibody. The method is characterized by using a spot detection method for detecting cells infected by human papilloma virus or pseudotype virus. The invention further discloses applications of the method in screening and identifying the neutralized monoclonal antibody against HPV, evaluating the immunity protectiveness of HPV vaccine, the potency test (ED50 test) of HPV vaccine, etc.

The invention provides peptides designed to be highly reactive with antibodies from patients infected with oncogenic HPV. Also disclosed is a method for their use in an immunoassay to detect HPV infection and HPV associated epithelial cell abnormalities, most notably those associated with premalignant and malignant epithelial cell lesions. The peptides and the disclosed method are particularly useful for diagnosing carcinomas of the uterine cervix, or pre-stages thereof, or those at risk of development of carcinoma. The detection can be effected on blood samples, or other bodily fluid or tissue, by ascertaining the presence of IgA or IgG antibodies against HPV 16 and/or 18.

An isolated sequence or peptide isolated from an E2, E4, E6, E7 early or late coding region of human papillomavirus (HPV) that is soluble in aqueous medium, and characterized by a linkage to another protein sequence or peptide isolated from the E2, E4, E6, E7 early or late coding region of HPV by a spacer sequence, wherein the isolated protein sequence or peptide consists of more than 50% hydrophilic amino acids, and is recognized by a specific antibody of HPV. Also disclosed are isolated protein sequences or peptides from Harvey Ras (H-Ras), Kirsten Ras (K-Ras), and phosphatase and tensin homologue (PTEN) tumor suppressor proteins and Chlamydia trachomatis heat shock protein 60 (CHSP60 groEL1) and methods for detecting or diagnosing cancer or cellular abnormalities.

The invention discloses a gene chip, a reagent and a kit for high-throughput typing detection of a human papilloma virus. The gene chip comprises a carrier membrane substrate, and a probe fixed on the substrate, wherein the probe is nucleotide which can hybridize with various types of DNA special segments of human papilloma virus; 5' end of the probe is labeled by amino, and a nucleotide sequence of the probe is any one of probe nucleotide sequences in an attached sequence list. The invention provides the gene chip for detecting various types of the human papilloma virus, and simultaneously provides a detection reagent for rapid and parallel detection of various types of HPVs (human papilloma virus) as well as for high-throughput analysis of a great sample size.

The present invention relates to a method of vaccinating a mammal against papillomavirus by administering papillomavirus virus-like particles transdermally to a mammal under conditions effective to induce an immune response to the papillomavirus.

The invention relates to a compound vaccine composition for preventing and treating human papillomavirus infection, a compound vaccine vaginal spray and uses thereof, and belongs to the field of vaccine preparations with targeted treatment indications. The product of the present invention can prevent cervical cancer and treat HPV infection; it is suitable for married women of any age; it can prevent and treat chronic cervicitis and cervical epithelial dysplasia caused by sexually transmitted HPV infection, including CIN I, II, III Degree, inhibit HPV reproduction, prevent cervical cancer.